Q
Quell Therapeutics
Engineered T-regulatory cell therapies for immune-driven diseases
At a glance
- Founded
- 2019
- Headquarters
- London, United Kingdom
- Sector
- Biotech & Life Sciences
- Power Law
- Colt$25–100M revenue
Latest news
Press, funding announcements and product moves mentioning Quell Therapeutics.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A3 investors entered at this stage
- ALAlbionVC
- UFUCL Technology Fund
- SYSyncona
Series B and later14 investors entered at this stage
- MMMonashee Investment Management
- MHMedizinische Hochschule Hannover
- RCRidgeback Capital
- KLKing's College London
- BCBritish Patient Capital
Janus Henderson Investors- BVBreakthrough Energy Ventures
- ULUniversity College London
- FFFuture Fund
- JCJeito Capital
Fidelity Investments- SISV Health Investors
- TMTekla Capital Management
- PVPoint72 Ventures
Ownership
Estimated cap table from Dealroom's shareholder data — share of equity by holder. Stakes as last recorded by Dealroom (2026). Percentages are indicative.
Some investors are hidden on this public profile. See the full cap table on Dealroom →
Source: Dealroom Talent Intelligence.
Global footprint
across markets
Market sentiment
An AI-synthesised read of the highest-engagement posts about Quell Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Quell Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.